SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:lup.lub.lu.se:7ec74219-66c4-4db5-9457-0d25926e0b70"
 

Search: id:"swepub:oai:lup.lub.lu.se:7ec74219-66c4-4db5-9457-0d25926e0b70" > Tasquinimod Is an A...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Isaacs, John T. (author)

Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment

  • Article/chapterEnglish2013

Publisher, publication year, extent ...

  • 2013

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:7ec74219-66c4-4db5-9457-0d25926e0b70
  • https://lup.lub.lu.se/record/3577906URI
  • https://doi.org/10.1158/0008-5472.CAN-12-2730DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Tasquinimod is an orally active antiangiogenic drug that is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer. However, the target of this drug has remained unclear. In this study, we applied diverse strategies to identify the histone deacetylase HDAC4 as a target for the antiangiogenic activity of tasquinimod. Our comprehensive analysis revealed allosteric binding (Kd 10-30 nmol/L) to the regulatory Zn2+ binding domain of HDAC4 that locks the protein in a conformation preventing HDAC4/N-CoR/HDAC3 complex formation. This binding inhibited colocalization of N-CoR/HDAC3, thereby inhibiting deacetylation of histones and HDAC4 client transcription factors, such as HIF-1 alpha, which are bound at promoter/enhancers where epigenetic reprogramming is required for cancer cell survival and angiogenic response. Through this mechanism, tasquinimod is effective as a monotherapeutic agent against human prostate, breast, bladder, and colon tumor xenografts, where its efficacy could be further enhanced in combination with a targeted thapsigargin prodrug (G202) that selectively kills tumor endothelial cells. Together, our findings define a mechanism of action of tasquinimod and offer a perspective on how its clinical activity might be leveraged in combination with other drugs that target the tumor microenvironment. Cancer Res; 73(4); 1386-99. (C) 2012 AACR.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Antony, Lizamma (author)
  • Dalrymple, Susan L. (author)
  • Brennen, W. Nathaniel (author)
  • Gerber, Stephanie (author)
  • Hammers, Hans (author)
  • Wissing, Michel (author)
  • Kachhap, Sushant (author)
  • Luo, Jun (author)
  • Xing, Li (author)
  • Bjork, Per (author)
  • Olsson, Anders (author)
  • Bjork, Anders (author)
  • Leanderson, TomasLund University,Lunds universitet,Immunologi,Forskargrupper vid Lunds universitet,Immunology,Lund University Research Groups(Swepub:lu)immu-tle (author)
  • ImmunologiForskargrupper vid Lunds universitet (creator_code:org_t)

Related titles

  • In:Cancer Research74:4, s. 1386-13991538-7445

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view